colorectal cancer Archives
Holowatyj receives National Cancer Institute MERIT Award
Jul. 19, 2023—Vanderbilt's Andreana Holowatyj, PhD, MSCI, has received the National Cancer Institute’s Method to Extend Research in Time Award to support her ongoing investigation into how early-onset colorectal cancer and its treatments impact reproductive health.
Selenium signal found in colorectal cancer: study
Jun. 29, 2023—An antioxidant transporter of the trace mineral selenium that protects against inflammatory bowel disease has the opposite effect in colorectal cancer, where it promotes tumor growth, researchers at Vanderbilt University Medical Center have reported.
New treatment option for metastatic colorectal cancer prolongs survival
Jun. 15, 2023—Research conducted at Vanderbilt points to a new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options.
Early-onset CRC germline genetic differences identified by race, ethnicity
Jun. 15, 2023—A Vanderbilt study that delved into genetic predisposition for early-onset colorectal cancer by race and ethnicity has identified differing germline risk variants.
Better adenoma detection
May. 4, 2023—Fluorescent nanoparticles clearly identified colonic adenomas — precursors to colorectal cancer — in mice, and the formulation should translate to clinical use in humans.
Colon cancer researchers awarded NCI grant for study of early lesions
Sep. 22, 2022—Vanderbilt researchers are studying precancerous lesions and early cancers in the colon, with the goal of developing new ways to prevent colorectal cancer, the nation’s second leading cancer killer.
Patients had ‘significant and clinically meaningful improvement’ in survival in fruquintinib clinical trial
Sep. 13, 2022—Patients with metastatic colorectal cancer who had not responded to other treatments had “significant and clinically meaningful improvement” in overall survival when treated with the oral targeted therapy fruquintinib.
Trial for colorectal cancer drug reaches primary endpoint
Aug. 17, 2022—A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration has met its primary endpoint of overall survival in a phase 3 clinical trial.
C. difficile may contribute to colorectal cancer: study
Jul. 28, 2022—A Vanderbilt study found that the bacterium Clostridioides difficile (C. difficile) may be a previously unrecognized contributor to colorectal cancer.
Researchers find potential new target against colorectal cancer
Jul. 21, 2022—by Bill Snyder Researchers at Vanderbilt University Medical Center have discovered a potential new target in the fight against colorectal cancer, the nation’s third most common malignancy and, next to lung cancer, the second leading cancer killer. This month in the journal Gastroenterology, R. Daniel Beauchamp, MD, Anna Means, PhD, and colleagues report that a...
Probing the tumor microenvironment
Jul. 12, 2022—Vanderbilt researchers used single-cell sequencing, imaging, and computational approaches to characterize the colonic tumor microenvironment, providing important insights to the components that play roles in colorectal tumor pathogenesis.
Choi, Short receive AGA Research Foundation Awards
Jun. 2, 2022—Two Vanderbilt researchers have received awards from the AGA Foundation, the charitable arm of the American Gastroenterological Association.
